NAROPIN 2 MG — DIN 02229411
ROPIVACAINE HYDROCHLORIDE : 2 MG · ASPEN PHARMACARE CANADA INC. · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is NAROPIN?
NAROPIN 2 MG contains ROPIVACAINE HYDROCHLORIDE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02229411, held by ASPEN PHARMACARE CANADA INC., supplied as SOLUTION for BLOCK/INFILTRATION ; EPIDURAL administration. Health Canada currently lists it as marketed, status dated 28-Jul-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NAROPIN used for?
NAROPIN (ropivacaine hydrochloride) is indicated for analgesia (acute pain management in connection with continuous epidural infusion or intermittent bolus administration e.g., postoperative or labour pain; field block e.g., infiltration) and anaesthesia (surgical anaesthesia in connection with epidural block for surgery, including Caesarean section; major nerve block e.g. brachial plexus block; field block e.g. infiltration).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ropivacaine cost around the world?
Ropivacaine is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Saudi Arabia publishes a public; South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 16 | 16 | EUR███.██ |
| Saudi Arabia | public | 5 | 12 | SAR███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
33 pack listings across 26 brand entries and 4 price bases, refreshed 03 Sep 2026. Ranges span every Ropivacaine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Ropivacaine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Ropivacaine, across 13 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 4 | 3 | ROPIVACAINE HYDROCHLORIDE INJECTION, USP | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 3 | 3 | NAROPIN | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 0 | ROPIVACAINE HYDROCHLORIDE INJECTION USP | No marketed DIN |
| ASTRAZENECA CANADA INC | 1 | 0 | NAROPIN INJ 7.5MG/ML | No marketed DIN |
| FORMATIVE PHARMA INC. | 1 | 0 | XFUSOR | No marketed DIN |
| TEVA CANADA LIMITED | 1 | 0 | ROPIVACAINE HYDROCHLORIDE INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | BLOCK/INFILTRATION ; EPIDURAL |
| Pack configuration (monograph) | 2 mg/mL for infusion: 100 and 200 mL Polybag; 5 mg/mL for injection: 20 mL Polyamp; 10 mg/mL for injection: 10 and 20 mL Polyamp |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Ropivacaine |
|---|---|
| ATC code | N01BB09 |
| AHFS class | 72:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02229411 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2229411 |
| Brand name | NAROPIN |
| Generic / active ingredient | ROPIVACAINE HYDROCHLORIDE : 2 MG |
| Market authorization holder | ASPEN PHARMACARE CANADA INC. |
| Health Canada schedule | Ethical |
| ATC code | N01BB09 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N01BB |
| Current status | MARKETED |
| Status date | 28-Jul-2017 |
| Original market date | 1997-04-14 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Ropivacaine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
6 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| NAROPIN | 5 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 02229415 |
| NAROPIN | 10 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 02229418 |
| ROPIVACAINE HYDROCHLORIDE INJECTION, USP | 10 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02439409 |
| ROPIVACAINE HYDROCHLORIDE INJECTION, USP | 5 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02439387 |
| ROPIVACAINE HYDROCHLORIDE INJECTION, USP | 2 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02439379 |
| NAROPIN INJ 7.5MG/ML | 7.5 MG | LIQUID | ASTRAZENECA CANADA INC | CANCELLED POST MARKET | 02229416 |
| ROPIVACAINE HYDROCHLORIDE INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED PRE MARKET | 02408589 |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 2 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED PRE MARKET | 02403285 |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02347830 |
| ROPIVACAINE HYDROCHLORIDE INJECTION USP | 5 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02347822 |
2 · Same class — other molecules in ATC N01BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | AMNIOCENTESIS TRAY 1% · ANTECUBITAL CENT VENOUS CATHETERIZATION KIT · ARTHROGRAM TRAY 1% · ATELOCOLLAGEN IMPLANT · +39 more | 72 | 26 | Yes |
| Lidocaine, Combinations | 2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP · 5% XYLOCAINE MPF WITH GLUCOSE 7.5% INJECTION · ARROW CENTRAL VENOUS CATHETERIZATION KIT · ARROW MULTI-LUMEN CENTRAL VENOUS CATHETER KIT · +55 more | 72 | 16 | Yes |
| Articaine, Combinations | 4% ASTRACAINE DENTAL WITH EPINEPHRINE 1:200,000 (0.005MG/ML) · 4% ASTRACAINE DENTAL WITH EPINEPHRINE FORTE 1:100,000 (0.01MG/ML) · ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION · ORABLOC 1:100,000 · +10 more | 18 | 12 | Yes |
| Bupivacaine | BUPIVACAINE HEAVY INJECTION BP · BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP .25% · +12 more | 42 | 10 | Yes |
| Mepivacaine | 3% POLOCAINE DENTAL · CARBOCAINE 1% · CARBOCAINE 2% · CARBOCAINE 3% · +7 more | 15 | 7 | Yes |
| Ropivacaine | NAROPIN · NAROPIN INJ 7.5MG/ML · ROPIVACAINE HYDROCHLORIDE INJECTION · ROPIVACAINE HYDROCHLORIDE INJECTION USP · +2 more | 13 | 6 | Yes |
| Bupivacaine, Combinations | BUPIVACAINE HCL 0.5% AND EPINEPHRINE 1:200,000 INJECTION · MARCAINE · MARCAINE 0.5% AND EPINEPHRINE 1:200,000 LIQ · MARCAINE E · +5 more | 12 | 5 | Yes |
| Prilocaine, Combinations | 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 · DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 · EMLA CREAM · EMLA PATCH · +1 more | 5 | 4 | Yes |
| Combinations | CETACAINE LIQUID · ORAQIX | 2 | 2 | Yes |
| Prilocaine | 4% CITANEST PLAIN DENTAL · DENTSPLY 4% PRILOCAINE HYDROCHLORIDE DENTAL INJECTION | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N01BA | Benzocaine · Chloroprocaine · Combinations,Of Anesthetics · Procaine · Tetracaine | 13 | 1 |
| N01BX | Phenol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is NAROPIN called?
The same molecule, Ropivacaine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Rivalast | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.